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Background: A lot of microRNAs (miRNAs) derived from viral genomes have been identified. Many of them play
various important roles in virus replication and virus-host interaction. Cellular miRNAs have been shown to participate
in the regulation of HIV-1 viral replication, while the role of viral-encoded miRNAs in this process is largely unknown.
Results: In this report, through a strategy combining computational prediction and deep sequencing, we identified
a novel HIV-1-encoded miRNA, miR-H3. MiR-H3 locates in the mRNA region encoding the active center of reverse
transcriptase (RT) and exhibits high sequence conservation among different subtypes of HIV-1 viruses. Overexpression
of miR-H3 increases viral production and the mutations in miR-H3 sequence significantly impair the viral replication of
wildtype HIV-1 viruses, suggesting that it is a replication-enhancing miRNA. MiR-H3 upregulates HIV-1 RNA transcription
and protein expression. A serial deletion assay suggests that miR-H3 targets HIV-1 5′ LTR and upregulates the promoter
activity. It interacts with the TATA box in HIV-1 5′ LTR and sequence-specifically activates the viral transcription. In
addition, chemically-synthesized small RNAs targeting HIV-1 TATA box activate HIV-1 production from resting CD4+ T
cells isolated from HIV-1-infected patients on suppressive highly active antiretroviral therapy (HAART).
Conclusions: We have identified a novel HIV-1-encoded miRNA which specifically enhances viral production and
provide a specific method to activate HIV-1 latency.
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MiRNA represents a class of small RNA ranged from 21-
24 nts, which plays important regulatory roles in animal,
plant, and fungi [1,2]. Virus-encoded miRNAs were ini-
tially identified from Epstein-Barr viruses [3]. Since then,
increasing virus-encoded miRNAs have been identified
[4,5]. Most of these miRNAs were reported in DNA viruses
such as Herpes and Polyoma viruses, but rarely in RNA vi-
ruses [5]. Because of the rapid development of deep se-
quencing technology which is much more sensitive and
quantitative than the conventional cDNA clone sequencing
method, more RNA virus-derived miRNAs have been dis-
covered especially from HIV-1, WNV and BLV [6-9].* Correspondence: zhangh92@mail.sysu.edu.cn
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unless otherwise stated.Most miRNAs repress gene expression through target-
ing the 3′ UTR of mRNA in cytoplasmic RISC for trans-
lation repression or mRNA degradation [1,10-12]. It has
been revealed that 5′ UTR and exons could also be the
targets of miRNAs for translation repression [13,14]. In
addition, miRNAs could also enter the nucleus and modu-
late gene expression at transcriptional level [15-17]. These
findings reveal multiple action modes are exploited by
miRNAs for gene expression regulation.
MiRNAs play important roles in the interaction be-
tween parasites and their hosts. Cellular miRNAs could
affect the viral replication, latency and mediate antiviral
defense. For example, miR-122 that is enriched in the
liver plays a key role in the accumulation of viral RNAs
of hepatitis C viruses [18]. A cellular miRNA effectively
restricts the accumulation of the retrovirus primate foamy
virus type 1 (PFV-1) in human cells [19]. Our group re-
ported that several miRNAs from resting human CD4+ T
cells repress the translation of viral proteins and contrib-
ute to the latency of HIV-1 [20]. Conversely, viral miRNAsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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antigens or impairing the host antiviral immune response.
For instances, SV40 miR-S1 down-modulates the produc-
tion of the viral T antigen (TAg), an early protein which
is not required during late infection [21]. An EBV-
encoded miRNA miR-BART5 targets the proapoptotic
factor PUMA to promote host cell survival [22]. Further-
more, an hCMV miRNA, miR-UL112-1, was reported to
inhibit the expression of the stress-induced ligand MICB
and enable hCMV to escape from the immune surveil-
lance by NK cells [23].
It has been reported that human immunodeficiency
virus type 1 (HIV-1) also encode several miRNAs and
other small RNAs. Bennasser et al. first performed a
computational prediction on HIV-1 encoded miRNAs
and found five pre-miRNAs candidates [24]. Subse-
quently, several groups identified HIV-1 encoded miR-
NAs from the nef or the TAR element [25-28]. Through
the new generation sequencing method, a number of
HIV-1-encoded small RNAs were discovered, some of
which exhibit the features of miRNA or small interfering
RNA (siRNA) [7,29].
These HIV-1 derived small RNAs have been shown to
modulate the cellular and/or viral gene expression. A
nef-derived miRNA-miR-N367 could block HIV-1 Nef
expression in vitro [28]. The expression of the TAR de-
rived miRNA could protect the infected cells fromFigure 1 Computational prediction of a novel HIV-1-encoded miRNA.
matic diagram of miR-H3 in the HIV-1 genome (start at 520 bp from the 5′
different HIV-1 subtypes. The accession number is listed beside each sequeapoptosis by down-regulating cellular genes involved in
apoptosis [27,30]. Since the expression levels of small
non-coding RNAs generated from RNA viruses are rela-
tively low, their roles in viral replication remain largely
elusive. Here, we initiated our project by searching for
new HIV-1-derived miRNA(s) and have identified a sur-
prising new function for a miRNA isolated from the re-
verse transcriptase sequence.
Results
Computational prediction of HIV-1-encoded miRNAs
By experimental methods, the architecture and secondary
structure of the entire HIV-1 RNA genome have been
clarified [31], which makes the prediction of HIV-1-
encoded miRNA(s) more accurate. With the online soft-
ware mireval (http://mimirna.centenary.org.au/mireval/),
we predicted nine putative HIV-1-encoded miRNAs in-
cluding the TAR region-derived miRNA which was re-
ported previously (data not shown) [26]. However, in
addition to TAR region-derived miRNA, only the precur-
sor sequence of miR-H3 could form the classic stem-loop
structure of miRNA according to the authentic secondary
structure of HIV-1 RNA (Figure 1A and Additional file 1:
Figure S1). The precursor sequence of miR-H3 is located
at the coding sequence of the HIV-1 reverse transcriptase
(RT), amino acids (a.a.) 174-191 (Figure 1B). The miR-H3-
3p mature sequence covers the sequence of the RT(A) The predicted secondary structure of miR-H3 precursor. (B) A sche-
end of RT gene). (C) Conservation analysis of miR-H3 precursor among
nce.
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among different HIV-1 subtypes (Figure 1C).
Experimental validation of miR-H3
To validate the expression of this miRNA, activated hu-
man primary CD4+ T-lymphocytes were infected with
wildtype HIV-1NL4-3 viruses. The deep sequencing on
small RNAs was conducted with total RNAs isolated
from infected or uninfected CD4+ T-lymphocytes. Eight-
een and one reads were found to correspond to 3p and
5p mature sequence of miR-H3 respectively (Figure 2A),
which suggests miR-H3-3p (miR-H3 in the following
text for convenience) is the guiding strand and miR-H3-
5p is the passenger strand. TAR-derived miRNA has the
similar reads in our deep sequencing data as the miR-
H3-3p (data not illustrated). The expression levels of
HIV-1-derived small RNAs are consistent with a recent
report [7]. However, miR-H3-3p was not described in
the previous studies, which may result from the different
programs used for miRNA prediction or different sam-
ple preparing methods for deep sequencing [4,7,29,32].
To confirm the expression of miR-H3-3p, RNase protec-
tion assay (RPA), real-time qRT-PCR and primer exten-
sion assay were conducted. In CD4+ T-cells infected
with wildtype HIV-1NL4-3, a small RNA was specifically
detected by RPA with a 32P-labeled probe complemen-
tary to miR-H3-3p (Figure 2B). The lower band corre-
sponded to the major fraction of the mature miR-H3-3p
sequence of 19 nts, and the upper band possibly corre-
sponded to the longer slicing products from the miR-H3
precursor, as suggested by the deep sequencing data.
These results were also confirmed by real-time qRT-
PCR assay on the total RNAs from HIV-1 virus-infected
primary CD4+ T lymphocytes (Figure 2C) and primer
extension assay (Additional file 1: Figure S2).
To further reveal whether the generation of miR-H3 is
dependent on the miRNA processing pathway, the pro-
teins required for miRNA precursor processing and
transport such as Drosha and Exportin-5 were knocked
down by siRNAs, and the expression of miR-H3-3p was
significantly reduced (Figure 2D). The subcellular distri-
bution analysis of miR-H3-3p suggested that it has equal
amount in the nucleus and the cytoplasm, indicating a
possible role it plays in the nucleus (Figure 2E).
MiR-H3 enhances viral production and replication
To investigate the possible effect of miR-H3 on viral rep-
lication, we generated a construct containing the precur-
sor of miR-H3 which could express miR-H3 efficiently
(Figure 3A). Mutations introduced to the precursor se-
quence significantly impaired the generation of mature
miR-H3-3p (Additional file 1: Figure S3), suggesting the
wildtype sequence is important for the proper processing of
the precursor. The overexpression of miR-H3 substantiallyenhanced the virus production when the Env-defective
HIV-1 clone, pNL4-3-deltaE-EGFP [33], was transfected
into HEK293T cells (Figure 3B). This result was also con-
firmed with the overexpression of miR-H3 in a cell line
named TZM-bl which contains an integrated HIV-1
promoter-driven luciferase gene [34] (Additional file 1:
Figure S4). Alternatively, when the precursor sequence of
miR-H3 was mutated to disturb its normal secondary struc-
ture without changing the corresponding amino acids in
pNL4-3-deltaE-EGFP (Additional file 1: Figure S5A), the
viral production was reduced (Figure 3C). To study the
effect of miR-H3 on the replication of wildtype HIV-1
viruses, we introduced the similar silent mutations into the
sequence of miR-H3-3p in the wildtype HIV-1NL4-3 to elim-
inate its precursor processing (Figure 3D top, Additional
file 1: Figure S5B). The reverse transcriptase activity assay
indicated that the mutations did not impair the activity of
reverse transcriptase at different concentrations (Figure 3D
bottom). The infectivity experiment of wildtype HIV-1 vi-
ruses suggested that the deficiency of miR-H3 substantially
reduced the replication of HIV-1 in activated human CD4+
T-lymphocytes (Figure 3E).
MiR-H3 increases viral RNA accumulation
Since we observed miR-H3 could enhance virus produc-
tion of the Env-defective HIV-1 clone pNL4-3-deltaE-
EGFP, whose virus production begins with transcription,
we firstly checked whether the transcription of HIV-1
total RNA was manipulated by miR-H3. Overexpression
of miR-H3 by the precursor construct upregulated the
expression of HIV-1 total RNAs transcribed from pNL4-
3-deltaE-EGFP plasmid (Figure 4A). The HIV-1 total
RNA is determined by the RNA transcripts containing
the HIV-1 R and U5 sequence [35]. Alternatively, when
the miR-H3-encoding sequence was mutated in the
pNL4-3-deltaE-EGFP plasmid, there was a significative
reduction of HIV-1 total RNAs transcribed from pNL4-
3-deltaE-EGFP (Figure 4B). We next checked whether
the HIV-1 protein production had been affected by miR-
H3. Western blot was performed using an antibody
against P24 protein which could also recognize its pre-
cursors P55 and P41 in the cytoplasm. The expression of
Gag proteins including P55, P41 and P24 were substan-
tially enhanced by miR-H3 (Figure 4C). These results
suggested that miR-H3 could facilitate the accumulation
of HIV-1 RNAs in the cells. This regulation could be
achieved via two ways: one is by enhancing the tran-
scriptional activity of the promoter, and another is by in-
creasing the stability of the RNAs.
MiR-H3 targets HIV-1 5′ LTR for promoter activation
To identify the targeting site of miR-H3 on the HIV-1
genome, different generations of lentiviral vectors, which
are derived from the HIV-1 genome with reduced viral
BA
D E
Figure 2 Experimental validation of miR-H3. (A) Mature miRNA sequences revealed by deep sequencing. Primary human CD4+ T-lymphocytes
isolated from healthy donors were activated with anti-CD3(1 μg/ml) and anti-CD28(5 μg/ml) antibodies and infected with wildtype HIV-1NL4-3 viruses. The
total RNAs from infected or uninfected CD4+ T-lymphocytes were extracted for deep sequencing on small RNA profiling. (B) RNase protection assay of
small RNAs (<200 nt) isolated from primary CD4+ T-lymphocytes infected with wild type HIV-1NL4-3 viruses or uninfected CD4
+ T-lymphocytes. The probe
is corresponding to 34-71 nt of the miR-H3 precursor. U6 RNA was detected as the loading control for RPA. (C) Real-time qRT-PCR was conducted on
total RNAs isolated from infected or uninfected activated CD4+ T-lymphocytes with primers for miR-H3-3p and miR-H3-5p respectively. MiR-31 was set as
a positive control, while U6 RNA expression was set as the internal control and set as 1 unit. (D) Two key factors in miRNA processing, DROSHA and
XPO5, were knocked-down with siRNAs, and the expression of miR-H3-3p from its precursor transfected into HEK293T was investigated by qRT-PCR as
described above. (E) Subcellular localization of miR-H3. HEK293T cells were transfected with pCMV-ΔR8.2 vector. Fouty-eight hrs later, nuclear and
cytoplasmic RNAs were isolated separately and the expression of tRNA-Gly, snoRNA-snoRD57 and miR-H3-3p were tested with real-time qRT-PCR. P-values
were calculated using the two tailed unpaired Student’s t-test with equal variances, n = 3. *p< 0.05, **p < 0.01, ***p < 0.001.
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Figure 3 Effect of miR-H3 on HIV-1 viral replication. (A) Ectopic expression of miR-H3 by a construct containing its precursor. Mature miR-H3-3p
sequence was tested with Real-time qPCR, an empty vector was transfected as control. (B) HEK293T cells were co-transfected with an Env-defective HIV-1
clone named pNL4-3-deltaE-EGFP and a miR-H3 precursor (pre-miR-H3) or the empty vector pEGFP-C1. The productions of P24 in the supernatant were
determined at 48 hrs post-transfection. (C) HEK293T cells were transfected with pNL4-3-deltaE-EGFP or a miR-H3 mutant named pNL4-3-deltaE-EGFP
miR-H3-mut. The productions of P24 in the supernatant were determined as described above. (D) Silent mutations were introduced to miR-H3 precursor
(labeled in red with underline) to eliminate its processing without altering the amino acids of the HIV-1 RT gene (top). The reverse transcriptase activity of
wildtype or miR-H3 deficient viruses was tested at different concentrations (bottom). (E) Equal amount (5 ng of P24 antigen) of wildtype and mutated
viruses were used for the infection of 2x106 activated primary CD4+ T-lymphocytes. The viral production in the supernatant was assayed by P24 ELISA at
several time intervals. P-values were calculated using the two tailed unpaired Student’s t-test with equal variances, n = 3. *p< 0.05, **p< 0.01.
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direct target of miR-H3. The first is pNL43-deltaE-EGFP
vector, which contains the entire HIV-1 genome except
for the env gene which was impaired and replaced with
a gfp gene. The second is pCMV-ΔR8.2 vector, which
contains similar genes with pNL4-3-deltaE-EGFP but
lacks of 5′ and 3′ LTR regions. The third is psPAX2 vec-
tor, which only contains gag, pol, tat, rev genes and rre
motifs (Figure 5A top). When co-transfected these vec-
tors with miR-H3 precursor or the empty vector, we
found that miR-H3 could only enhance the RNA expres-
sion of pNL4-3-deltaE-EGFP, but not that of the other
two vectors (Figure 5A bottom), suggesting its targeting
site is located on 5′ or 3′ LTR region. To clarify which re-
gion is the target of miR-H3, the LTR regions were cloned
into a luciferase reporter plasmid, pMIR- REPORT. The5′ LTR sequence was inserted into the upstream of firefly
luciferase gene to replace its CMV promoter, while the 3′
LTR sequence was inserted to the 3′ UTR region of the
firefly luciferase gene with a MMLV (moloney murine
leukemia virus) promoter whose activity is similar to that
of HIV-1 5′LTR. Ectopic expression of miR-H3 substan-
tially enhanced the luciferase activity of the construct
containing HIV-1 5′ LTR as the promoter, but not that of
the construct containing HIV-1 3′ LTR as the 3′-UTR
(Figure 5B). These results implied that miR-H3 targets
the 5′ LTR region of HIV-1 and most probably worked
through enhancing the promoter transcriptional activity.
MiR-H3 targets HIV-1 TATA box sequence-specifically
With computational prediction, we surprisingly found a
putative binding site of miR-H3 which covers the core
Figure 4 MiR-H3 upregulates HIV-1 total RNA and protein level. (A) Real-time qRT-PCR analysis of HIV-1 total transcripts from HEK293T cells
transfected with pNL4-3-deltaE-EGFP and a construct harboring the miR-H3 precursor or the empty vector. (B) pNL4-3-deltaE-EGFP or a
miR-H3-defective construct pNL4-3-deltaE-EGFP-miRH3-mut was transfected into HEK293T cells and total HIV-1 transcripts were assayed with
real-time qRT-PCR at 48 hrs post-transfection. GAPDH was set as the internal control. (C) Western blot of HIV-1 structural protein P55, P41 and P24
in HEK293T cells transfected with pNL4-3-deltaE-EGFP and the empty vector, the construct containing miR-150 precursor or miR-H3 precursor.
The β-actin was used as an internal control. P-values were calculated using the two tailed unpaired Student’s t-test with equal variances,
n = 3. *p < 0.05, ***p < 0.001.
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(Figure 6A). The TATA box motif in HIV-1 5′ LTR
starts two nucleotides further upstream and turns to the
sequence CATATAA in all subtypes except for subtype E
[36]. When mutations were introduced into the binding
site in the TATA box region, the enhancement effect on
promoter activity by miR-H3 was impaired (Figure 6B),
suggesting that the direct binding between the core pro-
moter and miR-H3 is required for its regulation. Fur-
thermore, we mutated the TATA box region of CMV
promoter to the same sequence as that of HIV-1 5′ LTR,
and found that the transcription of this mutant couldalso be enhanced by miR-H3 (Figure 6C). These results
suggest that the binding site in HIV-1 5′ LTR interacts
with miR-H3 sequence-specifically and is required for
the promoter activation induced by miR-H3. To investi-
gate whether miR-H3 increases the binding of general
transcription factors to the HIV-1 core promoter, we
carried out ChIP assay with antibody against the RNA
Polymerase II or the TATA box binding protein (TBP).
The result suggested miR-H3 enhanced the association
of both factors to the HIV-1 core promoter region
(Figure 6D). As Tat protein is a very important regula-
tory factor for HIV-1 transcription, we investigated
AB
Figure 5 MiR-H3 targets HIV-1 5′ LTR and upregulates HIV-1 promoter activity. (A) Effects of miR-H3 overexpression on different HIV-1
derived lentiviral vectors. pNL4-3-deltaE-EGFP, pCMV-ΔR8.2 and pAX2 are all HIV-1 derived lentiviral vectors with major difference in their 5′ and
3′ ends: pNL4-3-deltaE-EGFP contains HIV-1 LTRs, the other two contain most viral protein genes which were driven by a CMV promoter. MiR-H3
precursor was co-transfected with these vectors separately, and then the HIV-1 total transcripts from these plasmids were determined by
real-time qRT-PCR. (B) Dual-Luciferase assay was performed on the reporter construct with a HIV-1 5′-LTR functioning as the promoter or a HIV-1
3′-LTR sequence as the 3′-UTR region after co-transfection with the miR-H3 precursor or the empty vector. P-values were calculated using the
two tailed unpaired Student’s t-test with equal variances, n = 3. *p < 0.05, **p < 0.01.
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TAR motif affected the HIV-1 promoter activation
induced by miR-H3. Our data indicated that, in theabsence of Tat, miR-H3 still upregulated HIV-1 pro-
moter activity (Figure 6E). Alternatively, although the






Figure 6 (See legend on next page.)
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Figure 6 MiR-H3 targets the TATA box in HIV-1 5′ LTR via sequence specific manner. (A) Predicted binding site of miR-H3 in HIV-1 5′ LTR
with the TATA box highlighted. The MFE of this interaction is -19.2 kcal/mol. (B) Mutations (labeled in red with underline) were introduced to
the promoter, named HIV 5′ LTR mut. The effects of miR-H3 on promoter activity of wildtype or mutated promoter were determined with
dual-luciferase assay. The TATA box motif was indicated with a box. (C) Top, the TATA box motif of CMV promoter was replaced by the binding
site of miR-H3 on HIV-1 promoter (CMV-HIV_bs mt). The mutated nucleotides are indicated in red with underline. Bottom, the effects of miR-H3
on indicated promoter activities were determined with Dual-Luciferase assay as described above. The TATA box motif was indicated with a box.
(D) ChIP assay of HEK239T cells co-transfected with pNL4-3-deltaE-EGFP and pre-miR-H3 or the empty vector with antibody against Pol II or TBP
to examine the binding of these general transcription factors to the HIV-1 core promoter region. The normal IgG was used as a control. (E) The
effects of miR-H3 on HIV-1 promoter activity without Tat expression. (F) Effect of miR-H3 on the activity of a TAR region deficient (deletion of 470
to 492 bp in HIV-1 5′ LTR) HIV-1 promoter. (G) The effect of miR-H3 on another retrovirus promoter. A RSV promoter-derived luciferase reporter
construct was co-transfected with miR-H3 precursor or control vector, and the promoter activity was investigated by Dual-Luciferase assay.
P-values were calculated using the two tailed unpaired Student’s t-test with equal variances, n = 3. *p < 0.05, ***p < 0.001.
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affected (Figure 6F). Furthermore, miR-H3 did not
affect the promoter activities of another retrovirus,
Rous sarcoma virus (RSV), arguing against a non-
specific transcription regulation on retroviruses
(Figure 6G).
The small RNAs targeting HIV-1 TATA box activate viral
production from latently infected resting CD4+ T cells
HIV-1 latency in resting primary CD4+ T cells is the
major barrier for the eradication of the viruses in HIV-
1-infected patients on suppressive HAART. As miR-H3
has the enhancement activity on HIV-1 promoter, it is
interesting to examine whether TATA-targeting miRNA/
siRNA could be used to activate HIV-1 latency. To this
end, we synthesized various small RNAs including
miRNA mimics and siRNAs complementary to HIV-1
TATA box sequence. Among them, si-HIV-TATA-msig
contains three nucleotides of mismatch in its 5′ end to
avoid a possible RNA interference effects caused by the
attachment of the small RNA to the 3′ LTR of HIV-1
mRNA (Figure 7A). We found that some siRNAs en-
hanced the promoter activity more efficiently than the
synthesized miRNA mimics in HEK293T cells (with
the HIV-pro-Luc plasmid, data not shown). When co-
transfected with the Env-defective HIV-1 clone pNL4-3-
deltaE-EGFP, siRNAs against HIV-1 TATA box potently
increased the P24 antigen production with more stable
performances (Figure 7B). Finally, we examined the effect
of these small RNAs upon HIV-1 latency in resting CD4+
T cells directly isolated from HIV-1-infected individuals
receiving suppressive HAART. Post-integration HIV-1
latency in these cells was confirmed by the detection of in-
tegrated HIV-1 proviruses in the chromosomal DNA via
Alu-PCR (Additional file 1: Figure S6). Stimulation with
anti-CD3/anti-CD28 induced the production of a large
number of viral particles (Additional file 1: Figure S7).
These data suggest that the primary resting CD4+
T-lymphocytes isolated from the patients were latently in-
fected. After transfection with the siRNAs complementaryto HIV-1-TATA box, these resting CD4+ T cells generated
significantly more HIV-1 particles than those treated with
a negative control siRNA (Figure 7C). This data indicated
that a siRNA complementary to HIV-1 TATA box alone is
able to activate HIV-1 transcription in the latently-
infected resting CD4+ T-lymphocytes.Discussion
In this report, we found that a novel HIV-1-encoded
miRNA could upregulate its viral transcription by target-
ing the TATA box in the 5′ LTR. Several studies have re-
vealed that small non-coding RNAs (e.g. miRNA and
siRNA) target to gene promoters are able to induce gene
transcription activation or silence. For instance, miR-373
can activate the expression of E-cadherin and cold-shock
domain-containing protein C2 (CSDC2) through a target
site in their promoters [15]. Another miRNA, miR-423-
5p, induces transcriptional silencing by targeting a highly
conserved region in the promoter of progesterone recep-
tor (PR) gene [16]. At the same time, the potential of
synthetic small RNAs to manipulate gene transcription
was also explored. Morris and coworkers initially re-
ported the inhibition of the EF1α promoter with a
siRNA targeting approximately 100 bp upstream the
EF1α transcription start site (TSS) [37]. Several studies
subsequently reported that small RNAs could also in-
duce transcriptional gene activation by targeting gene
promoters [38,39]. These reports indicate the existence
of a small RNA guided transcription regulation mechan-
ism in the nucleus of mammalian cells. For the first
time, our study revealed that viruses have exploited
this host mechanism to regulate viral replication by
virus-encoded miRNAs. However, the targeting sites of
miRNA or siRNA on gene promoter in previous studies
distribute in a wide range (~1000 bp upstream of the
TSS). In this study, miR-H3 targets the key position for
transcription initiation -TATA box, wherein the poly-
merase II pre-initiation complexes (PICs) are assembled.
This finding raises the possibility that miRNAs directly
A B
C
Figure 7 Effect of small RNAs targeting HIV-1 TATA box upon HIV-1 production from resting CD4+ T cells isolated from HIV-1–infected
patients on suppressive HAART. (A) SiRNAs against HIV-1 TATA box were synthesized with the illustrated sequences. The TATA box motif was
indicated with a box. (B) The miR-H3 miRNA mimic or siRNA was co-transfected with pNL4-3-deltaE-EGFP into HEK293T cells. The productions of
P24 in the supernatant were determined with P24 ELISA at 48 hrs post-transfection. (C) Resting CD4+ T cells isolated from HIV-1-infected patients
on suppressive HAART were transfected with control siRNA or si-HIV-TATAs. After 72 hrs, HIV-1 virions in the supernatants were collected and viral
RNAs were isolated and amplified by real-time q RT-PCR with primer SK38 and SK39. The cutoff for virion-associated RNA is 500 copies per ml.
P-values were calculated using the two tailed unpaired Student’s t-test with equal variances, n = 3. *p < 0.05, **p < 0.01.
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mammalian cells.
The transcription activity of HIV-1 provirus is finely
modulated in different host cells, which is accomplished
through a lot of cellular transcription factors and viral
proteins. Cellular transcription factors such as Sp1,
NF-κB, NF-AT, LEF-1/TCF-1α, C/EBP, and CREB are
important for the activation of HIV-1 LTR-driven tran-
scription [40-49]; Conversely, cellular factors including
LBP-1, TDP-43, YY1 and P53 exhibit inhibitory effects
on LTR-driven transcription [50-54]. It is noteworthy
that the effects of many cellular factors are cell-type
dependent and there are complicated interaction among
these factors (more discussion see the review of Rohr
et al. [55]). A key viral regulator of HIV-1 transcription
activity is the regulatory protein-Tat, which is produced
during early phase of infection and binds to the trans-
activation-responsive region (TAR) located at the 5′-end
of viral mRNAs [56]. After binding, Tat recruits a diverse
series of transcriptional complexes to the viral promoterand activates transcription activity [57]. These com-
plexes include enzymes with histone and factor acetyl
transferase (HAT and FAT respectively) activities, which
modify chromatin conformation at the proviral integration
site [58], and a protein complex (P-TEFb) that hyper-
phosphorylates the carboxy-terminal domain (CTD) of
RNA polymerase II, thus promoting the initiation and
elongation of viral transcription [59,60]. Vpr and Nef also
have effects on HIV-1 transcription, which through the
interaction with Tat or up-regulating the expression of ac-
tivating factors such as NF-AT, NF-κB, and AP-1 [61-64].
In this study, we showed that miR-H3 is another HIV-1-
encoded cis- regulatory element, in addition to Tat, that
direct interacts with viral element and regulates transcrip-
tion activity. It is interesting to investigate whether the ef-
fect of miR-H3 is cell-type dependent and identify its
cellular co-factors. Our findings further reveal the com-
plexity of transcription regulation for HIV-1.
The advances in next-generation sequencing technol-
ogy have greatly fueled the discovery of small RNAs,
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functions are largely unexploited. One opinion about
these low expressed miRNAs is that they may not have
function due to the low expression levels. This idea is
reasonable according to the well-known paradigm that
miRNAs function in cytoplasm through targeting the
3′ UTR of mRNA for translation repression. This model
requires a considerable amount of miRNAs for their func-
tions since their targets are relatively highly expressed. But
our data suggest miR-H3 and many cellular miRNAs tar-
get the core promoter of HIV-1 virus and many important
genes (unpublished data), which are on the chromosomal
DNA with very limited copy number in the nucleus in
contrast to the massive mRNA molecules in the cyto-
plasm. Thus the requirement of the accumulation level of
these TATA box targeting miRNAs is relatively low. Our
data and previous studies on promoter targeting miRNAs
probably provide a novel function model for the low
expressed miRNAs.
Latent infection of HIV-1 is the major barrier for the
eradication of the viruses in patients on suppressive
HAART. The first step to remove latent viral reservoirs
is reactivating the latent proviruses. Several approaches
have been developed to activate latent virus transcription
including activating T lymphocytes with IL-2 or IL-2
plus anti-CD3/anti-CD28 antibody [65,66], protein kin-
ase C (PKC) activators (e.g. prostatin [67]), and activa-
ting transcription with small molecule inhibitors of
histone deacetylases without inducing host cell acti-
vation (such as, valproic acid (VPA), suberoylanilide
hydroxamic acid (SAHA))[68-70]. However, the first ap-
proach has been shown to cause serious toxic effects,
and the latters are speculated about causing global gene
expression activation with unpredictable side effects.
Thus, a HIV-1 provirus specific activating reagent is
ideal for purging the latent reservoir. In this study, we
demonstrated a HIV-1 encoded miRNA could activate
HIV-1 transcription in a sequence-specific manner, and
the synthesized small RNA induced viral production
from resting CD4+ T cells from patients receiving sup-
pressive HAART treatment. Together with our previous
finding that some cellular miRNAs have contributed to
the latency of HIV-1[20], a combination of the small
RNA(s) targeting to HIV-1 TATA box and the inhibitors
of these cellular miRNAs will provide a HIV-1 specific
approach for eradicating HIV-1 latent reservoir more
safely.
Conclusions
In this study, we identified a novel HIV-1-encoded
miRNA miR-H3, which potently enhances viral produc-
tion. Unlike most miRNAs that target the 3′ UTR of
mRNA for translation repression, miR-H3 targets the
TATA box in HIV-1 5′ LTR to upregulate the promoteractivity. It represents another HIV-1-encoded element,
in addition to Tat, that activates viral transcription via
cis regulation. These findings reveal a new layer of HIV-
1 replication regulation and may serve as the basis for




This research was approved by the Ethics Review Board of
The Eighth People’s Hospital at Guangzhou (Guangzhou
Infectious Disease Hospital, Guangzhou, China) and the
Ethics Review Board of Sun Yat-Sen University. HIV-1-
infected patients were recruited at The Eighth People’s
Hospital at Guangzhou and given written informed
consent with approval of the Ethics Committees. De-
identified human peripheral blood mononuclear cells
(PBMCs) from healthy blood donors were obtained from
local volunteers. We did not have any interaction with
these human subjects or protected information, and there-
fore no informed consent was required.
MiRNA in silico prediction
The genomic sequence of pNL4-3 was downloaded from
NCBI and submitted to web server of mireval (http://
mimirna.centenary.org.au/mireval/). A total of 9 miRNA
candidates including two associated with TAR regions
were suggested. These candidates were further filtered
by comparing their secondary structure with that of
HIV-1 genomic RNA [31] and coincident ones were
chosen for experimental validation. The miRNA precursor
structure prediction was performed with the Mfold web-
server [71]. Representative sequences of major HIV-1 sub-
types were downloaded from the HIV sequence database
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.
html). Alignment of these sequences was performed with
Clustal X program. The miRNA binding sites on HIV-1
were predicted with RNA-hybrid web server (http://bibi-
serv.techfak.uni-bielefeld.de/rnahybrid).
Cell culture
Sup-T1 and HEK293T cells were obtained from ATCC
(American Type Culture Collection, Manassas, VA) and
cultured according to ATCC recommendations. TZM-bl
cells were obtained from the AIDS Research and Refer-
ence Reagent Program, NIAID, US NIH. Human PBMCs
were isolated from the whole blood of healthy donors by
Ficoll-Hypaque Solution (HAO YANG, Tianjin, China).
The resting primary CD4+ T lymphocytes were then iso-
lated from PBMCs with CD4+ T Cell Isolation Kit II (BD).
Human primary PBMCs and CD4+ T cells were grown in
the RPMI 1640 conditioned media supplemented with
10% fetal bovine serum (FBS), 50 U/ml penicillin and
50 μg/ml streptomycin.
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The infectious HIV-1 clone (pNL4-3) and Env-defective
HIV-1 clone (pNL4-3-deltaE-EGFP) were obtained through
the AIDS Research and Reference Reagent Program,
NIAID, US NIH. The precursor of miR-H3 and hsa-miR-
150 were amplified by PCR and directionally cloned into
the downstream of the EGFP gene in the pEGFP-C1 vector
(BD Biosciences). The pNL4-3-miR-H3MT plasmid was
constructed by introducing mutations in the region for
miR-H3-3p mature miRNA without changing amino acid
code. Similar mutations were also introduced into non-
infectious HIV-1 clone, pNL4-3-deltaE-EGFP. HIV-pro-Luc
plasmid was constructed by replacing the promoter of
Luciferase gene in the pMIR-REPORT Luciferase vector
(Invitrogen) with HIV-1 5′ LTR sequence. MMLV-Luc-
HIV_3LTR plasmid was constructed by replacing the pro-
moter of Luciferase gene in the pMIR-REPORT vector with
the MMLV promoter and inserting the HIV-1 3′ LTR
downstream the luciferase gene. Several mutations were in-
troduced into miR-H3 binding site in the 5′ LTR sequence.
HIV-pro-Luc-mtTAR plasmid was constructed with delet-
ing 5′ half region of TAR motif (470 bp to 492 bp region in
HIV-1 5′ LTR) to abolish its functional secondary structure.
RSV-pro-Luc plasmid was constructed by replacing the
promoter of Luciferase gene in the pMIR-REPORT vector
with the RSV promoter. All the constructs were verified by
sequencing. The siRNAs against Drosha and Exportin-
5 genes were purchased from Dharmacon. Anti-β-actin
antibody (D6A8) was purchased from CST (Danvers, MA).
Anti-human CD3 and anti-human CD28 antibodies were
from BD (Palo Alto, CA). The rabbit anti-P24 antibody was
prepared by our lab.
Infection and transfection
Infectious HIV-1 clone pNL4-3 was transfected into 60%
confluent HEK293T cells (100 mm plate) using Lipofecta-
mine 2000 according to the manufacturer’s protocol
(Invitrogen). Viral supernatant was collected 2 days after
transfection and viral production was determined by P24
ELISA kit. Five ng P24 f infectious HIV-1 viruses were used
to infect 2X 106 activated human CD4+ T lymphocytes for
3 hrs at 37°C. The cells were then washed three times with
cold PBS and add fresh conditioned medium containing IL-
2 (10 ng/ml). Supernatants of cell culture were collected in
2-3 days interval and subject to P24 ELISA detection.
Transfection of HEK293Tand TZM-bl cells was performed
with Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. Transfection of primary CD4+
cells with small RNA was performed with RNAiMAX
(Invitrogen) according to the manufacturer’s protocol.
Quantitative real-time RT–PCR analysis
Total RNA from HEK293T or CD4+ T cells was isolated
with Trizol reagent (Invitrogen) and then subjectedto cDNA synthesis using PrimeScript RT reagent Kit
(Takara). All primers were annealed at 37°C and RT was
processed at 42°C. Quantitative PCR was performed with
SYBR Premix ExTaq II Kit (Takara) by following the
manufacturer’s instructions. The expressions of HIV-1
total RNAs were determined with the primer pair
HIVTotRNA-5 F/R. The HIV-1 RT activity assay was per-
formed by following the method described in Vermeire
et al. [72]. An in vitro-synthesized HIV-1 RNA, after quan-
tification [73], was used as the external control for meas-
uring virion-associated viral RNA. Quantification was
normalized to the housekeeping gene U6 or β-actin. All
primers for HIV-1 gene detection were listed in the add-
itional files. The relative expression levels were calculated
using the following equation: A = 2[Ct(ref) −Ct(ref ‐ control)] −
[Ct(sample) −Ct(sample ‐ control)].
Dual-luciferase reporter assay
HEK293T cells were seeded in 48-well plates (Corning)
at a density of 20,000 cells per well one day before trans-
fection. One to 5 ng of HIV-1 wildtype or mutated pro-
moter driven-firefly luciferase (FL) reporter and 2 ng
renilla luciferase (RL) constructs were co-transfected
with miRNA precursor/mock control into HEK293T
cells using Lipofectamine 2000 (Invitrogen) by following
the manufacturer’s protocol. After 24-48 hrs, FL and RL
activities were measured with the Dual-Glo luciferase
assay system according to the manufacturer’s instruc-
tions (Promega).
Protein analysis
Infectious or defective viral particle production in cell
cultures was determined with P24 ELISA kit by follow-
ing the manufacturer’s protocol. Western blotting was
carried out as described previously with some minor
modifications [74]. The anti-P24 or anti-β-actin anti-
bodies were used to detect HIV-1 P55, P41 and P24 or
β-actin protein respectively.
RNase protection assay (RPA)
The activated CD4+ T-cells were infected with viruses
produced from HIV-1 clone pNL4-3 or mock infected.
At 48 hrs post infection, the fresh CD4+ T-cells from the
same donor were co-cultured with the infected CD4+ T-
cells with a ratio of 3:1 for another 72 hrs. Then the total
RNAs were isolated with Trizol Reagent (Invitrogen) and
the small RNAs (<200 nt) were enriched by using the
mirVana miRNA isolation kit (Ambion). The procedure
of RPA described by Gilman was followed with some
minor modifications [75]. The RNA probe was a se-
quence complementary to nt 34/71 of miR-H3 precursor
and was synthesized from DNA templates by in vitro
transcription using the T7 RNA polymerase (NEB) and
radiolabeled by random incorporation of α-32 P UTP
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with 10 ug of small RNA overnight at 45°C. After the
hybridized RNAs were then treated with RNases A/T1,
the protected RNAs were separated by denaturing PAGE
(12%) and visualized by autoradiography.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed with Magna ChIP™ A/G Kit
(Millipore) by following the manufacture’s instruction.
Briefly, HEK293T cells were co-transfected with pNL4-
3-deltaE-EGFP and pre-miR-H3 or the empty vector. At
48 hrs post transfection, the cells were collected to carry
out ChIP assay with anti-Pol II (8WG16, Covance), TBP
(Abcam), or normal IgG antibodies. The HIV-1 pro-
moter sequence corresponding to -50 - (+)50 bp relative
to the TSS was detected with qPCR.
Additional file
Additional file 1: Figure S1. The genuine secondary structure of miR-H3
precursor corresponding sequence in HIV-1 genome by Watts et al [31].
Figure S2. Primer extension assay of miR-H3-3p. Total RNAs were isolated
from HEK293T cells transfected with a lentiviral vector pCMV-ΔR8.2 which
contains the miR-H3 precursor or a control plasmid for 48 hrs. A small RNA
band was detected only in the lane of pCMV-ΔR8.2 transfection by a probe
specific to miR-H3-3p sequence. Figure S3. Ectopic expression of miR-H3
by constructs containing its wildtype or mutated precursors. Top, the
mutated nucleotides were indicated in red; bottom, mature miR-H3-3p
sequence was tested with real-time qPCR and normalized to U6. The empty
vector was transfected as a control. Figure S4. The effect of miR-H3 on
integrated HIV-1 reporter system. TZM-bl cells, containing an integrated
HIV-1 promoter-driven luciferase cassette in chromosomal DNA, were
transfected with the construct harboring miR-H3 precursor or an empty
vector. The transcription activities of HIV-1 promoter were examined by
luciferase assay. Figure S5. MiR-H3-3p processed from mutated
pNL4-3-deltaE-EGFP (A) or pNL4-3 constructs (B). The plasmid were
transfected into HEK293T cells, 48 hrs later total RNAs were isolated and
miR-H3-3p expression was determined with qRT-PCR and normalized to
U6. Figure S6. Confirmation of integrated HIV-1 proviruses in the
chromosomal DNA from resting CD4+ T cells isolated from HIV-1-
infected patients on suppressive HAART using Alu-PCR. Figure S7. The
virus production was induced from resting CD4+ T cells isolated from
HIV-1-infected patients on suppressive HAART by anit-CD3/anti-CD28.
The viral production in the supernatant was measured by HIV-1 P24
ELISA.
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